Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CNX-774 是一种选择性的、具有口服活性的、不可逆的 BTK 抑制剂 (IC50<1 nM)。它能够特异性靶向 Btk 的 Cys 481进行共价修饰。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 298 | 现货 | ||
2 mg | ¥ 428 | 现货 | ||
5 mg | ¥ 689 | 现货 | ||
10 mg | ¥ 1,120 | 现货 | ||
25 mg | ¥ 1,880 | 现货 | ||
50 mg | ¥ 2,970 | 现货 | ||
100 mg | ¥ 4,970 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 773 | 现货 |
产品描述 | CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM). |
靶点活性 | BTK:<1 nM |
体内活性 | 在细胞试验中,CNX-774以BTK的ATP结合位点Cys-481残基为靶点从而抑制其活性(IC50:1-10 nM)。 |
激酶实验 | In vitro kinase assays: The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity. |
别名 | CNX 774 |
分子量 | 499.5 |
分子式 | C26H22FN7O3 |
CAS No. | 1202759-32-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 2 mg/mL (4.0 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (186.2 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.002 mL | 10.01 mL | 20.02 mL | 50.0501 mL |
DMSO | 5 mM | 0.4004 mL | 2.002 mL | 4.004 mL | 10.01 mL |
10 mM | 0.2002 mL | 1.001 mL | 2.002 mL | 5.005 mL | |
20 mM | 0.1001 mL | 0.5005 mL | 1.001 mL | 2.5025 mL | |
50 mM | 0.04 mL | 0.2002 mL | 0.4004 mL | 1.001 mL | |
100 mM | 0.02 mL | 0.1001 mL | 0.2002 mL | 0.5005 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CNX-774 1202759-32-7 Angiogenesis Tyrosine Kinase/Adaptors BTK Bruton tyrosine kinase Btk B-cell CNX 774 BCR Inhibitor inhibit CNX774 autoimmune inhibitor